Pharmaceutical company Dr Reddy's Laboratories Ltd (BSE:500124)(NSE:DRREDDY) (NYSE:RDY) on Wednesday announced the availability of Bortezomib for Injection 3.5 mg/vial for intravenous use only in the US cancer market.
The company added that the Bortezomib for Injection 3.5 mg/vial has been approved by the US Food and Drug Administration (USFDA) via a 505(b)(2) new drug application (NDA) pathway.
In addition, the US FDA has approved the company's Bortezomib for Injection 3.5 mg/vial for the treatment of adult patients with multiple myeloma as well as for the treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy.
Dr Reddy's Laboratories stated that it is committed to providing affordable and innovative medicines for healthier lives. It operates through three businesses: Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products.
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886